Vol. 4 No. 4 (2024)
Reimbursement Reviews

Efgartigimod Alfa (Vyvgart)

decorative image of the issue cover

Published April 4, 2024

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses efgartigimod alfa (Vyvgart), 20 mg/mL solution, 10 mg/kg administered as an IV infusion over 1 hour once weekly for 4 doses (i.e., weeks 0 to 3). For patients weighing 120 kg or more, the recommended dose of efgartigimod alfa is 1,200 mg (3 vials) per infusion.
  • Indication: For the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.